Vertex Pharma received European Commission Approval for SYMKEVI With KALYDECO

▴ Vertex Pharma received European Commission Approval for SYMKEVI With KALYDECO
The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations

Vertex Pharmaceuticals Incorporated recently announced that the European Commission has granted approval of the label extension for SYMKEVI (tezacaftor/ivacaftor) with KALYDECO (ivacaftor), to include the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or one copy of the F508del mutation and one copy of one of 14 mutations in the CFTR gene that result in residual CFTR activity: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.

“With this approval, children with CF in Europe ages 6 to 11 years with the most common mutation, F508del, have a new treatment option and children with certain residual function mutations will, for the first time, have a treatment option available that addresses the underlying cause of their CF,” said Reshma Kewalramani, M.D., Chief Executive Officer and President at Vertex. “Today’s approval brings us closer to our ultimate goal of providing medicines for all people with CF.”

SYMKEVI (tezacaftor/ivacaftor) with KALYDECO (ivacaftor) will be immediately available to additional eligible patients in Germany and will be available shortly in countries that have entered into innovative long-term reimbursement agreements with Vertex, including the UK, Denmark and the Republic of Ireland. In all other countries, Vertex will work closely with relevant authorities in Europe to secure access for eligible patients.

In Europe, SYMKEVI (tezacaftor/ivacaftor) with KALYDECO (ivacaftor) is already approved for the treatment of people with CF ages 12 years and older who have either two copies of the F508del mutation in the CFTR gene, or one copy of the F508del mutation and a copy of one of the following 14 mutations in which the CFTR gene results in residual CFTR protein activity: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.

Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

Tags : #VertexPharmaceuticals #LatestNewsonVertexPharmaceuticals28thNov #LatestPharmaNews28thNov #LatestResearchonCysticFibrosis28thNov #Germany #Europe

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-




Trending Now

Dr. Priti Mehta, a Pediatric hematologist Oncologist explains the facts about Pre-implantation genetic diagnosisJanuary 21, 2021
The best way to lose weight is to not think about losing weight says Karishma Shah, Nutrition ConsultantJanuary 21, 2021
Demystifying Greenfield Pharma projects and Investment for the beginnersJanuary 21, 2021
Maharashtra COVID Update: Over 50,000 given COVID vaccine shots in three sessions so far January 21, 2021
1,12,007 beneficiaries vaccinated against Coronavirus, covering 11% health workersJanuary 21, 2021
Kerala continues to report surge in COVID cases with 6815 new casesJanuary 21, 2021
US studies claims vaccines are effective against the new Covid-19 strains January 21, 2021
Madhya Pradesh: Bird Flu virus found in 32 districts of state so farJanuary 20, 2021
Karnataka Health Minister expresses hope of launching Arogya Karnataka emergency health servicesJanuary 20, 2021
India starts shipments of Made in India COVID-19 Vaccines to neighbouring countriesJanuary 20, 2021
COVID-19 recovery rate improves to 98.13 pct in JharkhandJanuary 20, 2021
National COVID-19 recovery rate improves to 96.70 per centJanuary 20, 2021
Benefits of coconut waterJanuary 20, 2021
The RSA Group welcomes Eleanor Davies as Managing PartnerJanuary 19, 2021
Mask-wearing linked to reduced COVID-19 transmission, US modelling study suggestsJanuary 19, 2021
Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T TherapyJanuary 19, 2021
FUJIFILM Diosynth Biotechnologies begins production of two COVID-19 vaccinesJanuary 19, 2021
Fried food intake linked to heightened serious heart disease and stroke riskJanuary 19, 2021
‘’What is more dangerous is that we don't have any kind of criteria to be a coach,’’ says Parag Patil, Founder, LetzRun India, and MaxFit IndiaJanuary 19, 2021
‘’The younger generation must understand that health and fitness is at least a Forty-year commitment, and not a four-month game,’’ says Shreeharsh Deshmukh, Trainer, and Nutritionist, The Fit problemJanuary 19, 2021